Answers are grounded in this paper and cite their sources.
Silk sericin has emerged as a promising biomacromolecule for tissue engineering and nanotechnology-enabled drug delivery because of its biocompatibility, biodegradability, antioxidant and anti-inflammatory potential, and versatile processing properties. However, the global development and thematic structure of sericin-focused biomedical research have not been comprehensively mapped. This study evaluated research trends in silk sericin biomaterials for tissue engineering and nanotechnology-enabled drug delivery using a Scopus-based bibliometric approach. A total of 1,273 publications published between 1998 and 2025 were retrieved using a reproducible TITLE–ABS–KEY search strategy. Annual publication output, document types, subject areas, countries, institutions, authors, journals, citation patterns, author-keyword co-occurrence, and international collaboration networks were analyzed using Scopus data and VOSviewer. Publication output increased substantially after 2014 and reached its highest level in 2025. Original research articles constituted the dominant document type, accounting for 73.37% of the retrieved publications. Materials Science, Engineering, Biochemistry, Genetics and Molecular Biology, Chemical Engineering, and Chemistry were the principal contributing subject areas. China produced the largest number of publications, followed by India, while Thailand and the United States shared third place. Keyword analysis identified prominent themes involving silk-based biomaterials, tissue engineering, wound healing, hydrogels, drug delivery, nanoparticles, electrospinning, and antimicrobial applications. The findings indicate that sericin research has developed into a rapidly expanding multidisciplinary field; however, thematic and formulation-related diversification has progressed more rapidly than clinical, regulatory, and manufacturing consolidation. Future studies should prioritize standardized extraction and characterization, reproducible formulation protocols, comparative evaluation, long-term in vivo validation, scalable production, and regulatory alignment to support the development of clinically relevant sericin-based biomedical platforms.
No takes yet. Share an insight, caveat, or question.
Zıkşahna et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: